RxDoctor Payments Data

Tal Mednick, MD

Neurology · Commack, NYNPI 1700105590

Payments from drug & device makers

$6,206in general payments, 2019–2025

Across 315 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$731
  • Pfizer$435
  • Lundbeck LLC$337
  • Sumitomo Pharma America, Inc.$256
  • Amgen$254
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$240%
  • Food & beverage$6,16399%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,206 in reported general payments places this provider in the 65th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$268,788
Medicare patients
327
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4621$167,324
UbrelvyUbrogepant27$39,116
QuliptaAtogepant31$33,019
Nurtec OdtRimegepant Sulfate17$25,094
AptiomEslicarbazepine Acetate17$24,872
Aimovig AutoinjectorErenumab-Aooe17$17,690
Ajovy AutoinjectorFremanezumab-Vfrm14$10,519
Topiramate ErTopiramate19$7,709
DilantinPhenytoin Sodium Extended20$7,146
Gabapentin103$3,057
Levetiracetam71$2,733
Rasagiline Mesylate13$2,652
Carbamazepine ErCarbamazepine13$2,377
Carbidopa-LevodopaCarbidopa/Levodopa58$1,974
Oxcarbazepine29$1,618

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$115$167,32421 claims
AbbVieUbrelvy, Qulipta$1,647$72,13658 claims
PfizerNurtec Odt, Dilantin$435$32,23937 claims
Sunovion Pharmaceuticals Inc.Aptiom$142$24,87217 claims
Upsher-smith Laboratories LLCTopiramate$21$57228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,623 neurology providers in New York.

Other neurology in Commack

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →